Boston Scientific posts positive stroke prevention data for Watchman

Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results

Boston Scientific (NYSE:BSX), a maker of medical devices for interventional specialties, closed Monday at $62.92, down 9.03%. The stock moved lower on Monday as investors analyzed new clinical trial information on the company’s Watchman heart implant. Trading volume reached 39.9 million shares, coming in about 163% above its three-month average of 15.2 million shares. Boston Scientific IPO'd in 1992 and has grown 1370% since going public.How the…

Boston Scientific posts positive stroke prevention data for Watchman

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and efficacy goals in the closely watched CHAMPION-AF study.

Boston Scientific (BSX) Stock Plunges 9% on Watchman Trial Concerns and Rating Cut

Key Takeaways BSX shares plunged 9% to $62.93, marking the lowest closing price since January 2024 CHAMPION-AF trial data for Watchman FLX demonstrated non-inferiority to anticoagulants, yet revealed an elevated ischemic stroke incidence (3.2% versus 2%) Raymond James reduced its rating from Strong Buy to Outperform and lowered the price target from $97 to $88 The rating adjustment reflected decelerating expansion in U.S. electrophysiology and …

Data Highlights the WATCHMAN FLX Device

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results…